http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2380651-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-25 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2006-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33e1771068f7ff2e0859080164b615fd |
| publicationDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2380651-T3 |
| titleOfInvention | Biomarkers and procedures to determine the sensitivity to modulators of reciprocator 2 of vascular endothelial growth factor |
| abstract | An in vitro method for identifying a mammal that will respond therapeutically to a procedure for the treatment of cancer comprising administering a VEGFR-2 modulator, in which the method comprises: (a) measuring at least one biological sample of mammal obtained at from the mammal, the level of at least one biomarker that is chosen among the biomarkers of Table 1 (b) follow the mammal's exposure to the VEGFR-2 modulator, measuring at least one biological sample of the mammal obtained from the mammal , the level of at least one biomarker, in which the difference in level of at least one biomarker measured in stage (b) compared to the level of at least one biomarker measured in stage (a) indicates that the mammal will respond therapeutically to said cancer treatment procedure and in which at least one biomarker is collagen IV. |
| priorityDate | 2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1089.